X4 Pharmaceuticals, Inc. - Common Stock - Nakit Akışı (NASDAQ:XFOR) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit -58.82 M-70.91 M-77.1 M-96.51 M-130.9 M-85.62 M -92.85 M Yatırım faaliyetlerinden elde edilen nakit -1.36 M-615 K-103 K-14.88 M66.99 M8.15 M 30.54 M Finansman faaliyetlerinden elde edilen nakit 12.39 M74.25 M117.23 M88.52 M20.29 M238.63 M 238.63 M Serbest nakit akışı -60.18 M-71.52 M-77.2 M-96.57 M-130.9 M-85.62 M -92.85 M

Haberler

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

X4 Pharmaceuticals WHIM sendromu ilacına AB onayı aldı

Stifel, X4 Pharmaceuticals hissesi için tavsiyesini korudu

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals Nadir Hematolojiye Odaklanıyor

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval